Coherus BioSciences, Inc. (NASDAQ:CHRS) Shares Sold by Tudor Investment Corp Et Al

Tudor Investment Corp Et Al trimmed its stake in Coherus BioSciences, Inc. (NASDAQ:CHRS – Get Rating) by 86.5% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 23,610 shares of the biotechnology company’s stock after selling 151,480 shares during the quarter. Tudor Investment Corp Et Al’s holdings in Coherus BioSciences were worth $227,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Captrust Financial Advisors boosted its holdings in shares of Coherus BioSciences by 1,461.0% during the first quarter. Captrust Financial Advisors now owns 2,404 shares of the biotechnology company’s stock worth $31,000 after purchasing an additional 2,250 shares during the period. Eagle Bay Advisors LLC increased its stake in shares of Coherus BioSciences by 136.1% in the second quarter. Eagle Bay Advisors LLC now owns 3,891 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 2,243 shares during the last quarter. King Wealth acquired a new stake in Coherus BioSciences during the second quarter valued at $73,000. Verition Fund Management LLC purchased a new position in Coherus BioSciences in the third quarter valued at about $103,000. Finally, Mutual of America Capital Management LLC increased its position in Coherus BioSciences by 18.9% in the 3rd quarter. Mutual of America Capital Management LLC now owns 12,835 shares of the biotechnology company’s stock worth $123,000 after purchasing an additional 2,042 shares during the last quarter. 99.45% of the stock is owned by institutional investors and hedge funds.

Coherus BioSciences Stock Down 9.6 %

Shares of CHRS stock opened at $6.24 on Friday. Coherus BioSciences, Inc. has a 12 month low of $5.58 and a 12 month high of $14.11. The firm has a market cap of $496.77 million, a PE ratio of -1.66 and a beta of 0.92. The stock has a 50 day moving average of $8.31 and a 200-day moving average of $8.48.

Coherus BioSciences (NASDAQ:CHRS – Get Rating) last released its earnings results on Monday, March 6th. The biotechnology company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.12). Coherus BioSciences had a negative net margin of 138.24% and a negative return on equity of 422.10%. The company had revenue of $45.35 million for the quarter, compared to analyst estimates of $45.72 million. During the same quarter in the previous year, the company earned ($0.60) earnings per share. As a group, equities analysts predict that Coherus BioSciences, Inc. will post -1.44 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on CHRS shares. JPMorgan Chase & Co. dropped their price objective on Coherus BioSciences from $13.00 to $11.00 and set a “neutral” rating on the stock in a report on Monday, November 14th. Maxim Group cut their price target on shares of Coherus BioSciences to $15.00 in a report on Thursday, November 17th. Mizuho reduced their price target on Coherus BioSciences from $28.00 to $21.00 and set a “buy” rating for the company in a research report on Wednesday, November 16th. HC Wainwright cut their price objective on Coherus BioSciences from $30.00 to $26.00 and set a “buy” rating on the stock in a research note on Tuesday. Finally, Barclays decreased their target price on Coherus BioSciences from $15.00 to $13.00 and set an “overweight” rating for the company in a research report on Wednesday. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, Coherus BioSciences currently has an average rating of “Moderate Buy” and an average price target of $15.50.

Coherus BioSciences Company Profile

(Get Rating)

Coherus BioSciences, Inc is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. Its products include UDENYCA and Coherus COMPLETE. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.